<DOC>
	<DOCNO>NCT00146757</DOCNO>
	<brief_summary>The main objective study evaluate safety pharmacokinetics ( PK ) enzyme replacement therapy recombinant human alpha-L-iduronidase [ Aldurazyme® ( laronidase ) ] mucopolysaccharidosis I ( MPS I ) patient le 5 year old . Efficacy measurement also evaluate study .</brief_summary>
	<brief_title>A Study Evaluating Safety Pharmacokinetics Aldurazyme® ( Laronidase ) MPS I Patients Less Than 5 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>Written inform consent require parent ( ) legal guardian ( ) prior protocolrelated procedure perform . ( A separate inform consent request parent ( ) genotyping , independent inclusion . ) Be le 5 year age time enrollment . Have confirm iduronidase deficiency fibroblast leukocyte alphaLiduronidase enzyme activity level le 10.0 % low limit normal range , detection range measure laboratory . Have clinical diagnosis MPS I base genotyping . Documentation his/her medical record parent ( ) legal guardian ( ) counsel consultation regard HSCT order assure parent ( ) legal guardian ( ) fully inform regard risk benefit alternative treatment patient eligible trial severe manifestation MPS I neurodegeneration . The patient consideration undergone hematopoietic stem cell transplantation ( HSCT ) . The patient acute hydrocephalus time enrollment . The patient clinically significant organic disease ( exception symptom relate MPS I ) include : cardiovascular , hepatic , pulmonary , neurologic , renal disease , serious intercurrent illness , extenuate circumstance , opinion Investigator , would preclude participation trial potentially decrease survival . The patient receive investigational product within 30 day prior trial enrollment . The patient know severe hypersensitivity Aldurazyme® ( laronidase ) component delivery solution .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>